• An orally bioavailable, synthetic derivative of propylpentanoic acid that inhibits HDACs and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis
    • HDAC inhibitors have been shown to downregulate angiogenesis-related gene expression in tumor cells.
    • Currently FDA approved for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in epilepsy, and prophylaxis of migraine headaches
    • Recommended dose for oncology: 10 mg/kg PO daily (titrate for 75–100 μg/mL plasma trough level)
    • Half-life: 9 to 19 hours
    • Metabolism: Weak CYP2C9 and CYP2C19 substrate
    • Side effects: Abdominal pain, alopecia, blurred henia, dizziness, somnolence
    Other topics in Targeted and Immunotherapy Agents